Država: Malta
Jezik: angleščina
Source: Malta Medicines Authority
deferoxamine 500 mg
Novartis Pharmaceuticals UK Limited
V03AC01
deferoxamine
powder for solution for injection
Authorised
2005-08-01
DESFERAL ® Vials 500mg (desferrioxamine mesilate) PATIENT INFORMATION LEAFLET Read all of this leaflet carefully before you start using this medicine Keep this leaflet. You may need to read it again. If you have further questions, please ask your doctor or pharmacist. This medicine has been prescribed only for you. Do not give it to anybody else or use it for any other illnesses. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Desferal ® is and what it’s used for..................................................................... 2 2. Things to consider before you take Desferal ® .............................................................. 3 3. How to take Desferal.................................................................................................... 6 4. Possible side effects..................................................................................................... 9 5. How to store Desferal................................................................................................. 11 6. Further information..................................................................................................... 12 7. Information for the health care professional.............................................. .. ................ 12 1. WHAT DESFERAL IS AND WHAT IT’S USED FOR WHAT DESFERAL IS Desferal contains the active substance desferrioxamine, which is a so-called “chelator”. It is used to remove excess iron or aluminium from the body. WHAT DESFERAL IS USED FOR Repeated blood transfusions may be necessary in patients suffering from certain types of ane Preberite celoten dokument
Page 1 of 18 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT DESFERAL® 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: N-[5-(3-[(5-aminopentyl)-hydroxycarbamoyl] propionamido)pentyl]-3- ([5-(N- hydroxyacetamido)-pentyl]-carbamoyl)-propionohydroxamic acid monomethane sulphonate (= desferrioxamine methane sulphonate). One vial contains 500 mg desferrioxamine methane sulphonate. For a full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Vials containing 500 mg powder for solution for injection. 4. CLINICAL PARTICULARS 4.1. INDICATIONS THERAPEUTIC Monotherapy iron chelation treatment for chronic iron overload, e.g. • transfusional hemosiderosis, as seen in thalassemia major, sideroblastic anemia, autoimmune hemolytic anemia, and other chronic anemias. • idiopathic (primary) hemochromatosis in patients in whom concomitant disorders (e.g. severe anemia, cardiac disease, hypoproteinemia) preclude phlebotomy • iron overload associated with porphyria cutanea tarda in patients unable to tolerate phlebotomy. Treatment for acute iron poisoning. Treatment for chronic aluminum overload in patients with end-stage renal failure (under maintenance dialysis) with: • aluminium-related bone disease, • dialysis encephalopathy or • aluminium-related anaemia. Page 2 of 18 DIAGNOSTIC Diagnosis of iron or aluminium overload. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION TREATMENT FOR CHRONIC IRON OVERLOAD The main aim of chelation therapy in iron overload in well-controlled patients is to maintain an iron balance and to prevent haemosiderosis, while Preberite celoten dokument